Planet Labs Contingent consideration fair value adjustments increased by 94.6% to $1.40M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 12.8%, from $1.24M to $1.40M.
Increases often signal that acquired assets are performing better than expected, requiring higher future payouts, while decreases may suggest lower-than-anticipated success in R&D milestones.
This reflects the periodic adjustments to the fair value of earn-out provisions or milestone payments related to past bu...
Standard for R&D-heavy firms that frequently acquire biotech companies with milestone-based deal structures.
operating_business_combination_contingent_consideration__7f0be7| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$423.00K | -$104.00K | -$396.00K | -$101.00K | $2.03M | $1.24M | $276.00K | -$41.00K | $717.00K | $1.40M |
| QoQ Change | — | — | — | — | — | — | — | — | — | +75.4% | -280.8% | +74.5% | >999% | -38.9% | -77.7% | -114.9% | >999% | +94.6% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | +76.1% | >999% | +412.4% | — | +59.4% | -64.6% | +12.8% |